Meeting Coverage:

American Academy of Ophthalmology

AAO: 2022

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Show Description +

Himani Goyal, MD, and Adanna Udeh, MD, discuss the findings of a retrospective chart review evaluating the efficacy of netarsudil (Rhopressa, Aerie Pharmaceuticals), a rho kinase (ROCK) inhibitor, for the treatment of corneal edema in patients with Fuchs endothelial dystrophy.

Posted: 10/01/2022

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Himani Goyal, MD, and Adanna Udeh, MD, discuss the findings of a retrospective chart review evaluating the efficacy of netarsudil (Rhopressa, Aerie Pharmaceuticals), a rho kinase (ROCK) inhibitor, for the treatment of corneal edema in patients with Fuchs endothelial dystrophy.

Posted: 10/01/2022


Please log in to leave a comment.

More From AAO: 2022 Coverage